<?xml version="1.0" encoding="utf-8"?>
	<collection>
		
	
		<source>SourceData</source>
		
	
		<date>2019-04-19</date>
		
	
		<key>sourcedata.key</key>
		
	
		<document>
			
		
			<id>5286370 Figure_1-A-B</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 1-A-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-A-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Mice bearing established A375 were treated with vehicle (n=7), PLX4720 (n=5) bevacizumab (n=7) or COMBO (n=5). Tumor growth is expressed as % change of the initial tumor, **P &amp;lt; 0.01, ***P &amp;lt; 0.001 versus vehicle (PLX4720 P = 0.0049; bevacizumab P = 0.0003; P = 4.86E-10) ŦP &amp;lt; 0.05 compared to PLX4720 (P = 0.015). (B) Mice bearing established COLO205 were treated with vehicle (n=7), PLX4720 (n=8) bevacizumab (n=7) or COMBO (n=8). Tumor growth is expressed as % change of the initial tumor, ***P &amp;lt; 0.001 versus vehicle (PLX4720 P = 2.75E-05; bevacizumab P = 2.96E-05; COMBO P = 2.13E-07) Ŧp &amp;lt; 0.05 compared to PLX4720 (P = 0.039).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_1-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 1-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C) Melanoma MC-1 cells (5 x 105) were injected into the tail vein of CD1 mice. Lung colonization was assayed by HE staining and calculating the number of nodules and their total area normalized per the total area of the lungs. The mice analyzed were: start point, n=6; vehicle, n=7; PLX4720, n=6; bevacizumab, n=6; COMBO, n=7, *P &amp;lt; 0.001 versus vehicle (P = 0.031).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_1-D-E</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 1-D-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_1-D-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) Representative images of tumor cell proliferation determined by immunofluorescence Ki67 staining in A375 xenografts treated as indicated. Bar graphs indicate the Ki67+ area/tumor area (n=4 tumors), ***P &amp;lt; 0.001 versus vehicle (PLX4720 P = 2.83E-08; bevacizumab P = 4.25E-13; COMBO P = 6.16E-08). (E) Representative images of tumor cell apoptosis determined by immunofluorescence staining with TUNEL in A375 xenografts treated as indicated. Bar graphs indicate the TUNEL+ area/tumor area (n=3 tumors). ***P &amp;lt; 0.001 versus vehicle (P = 6.2.7E-10).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:25E</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="271"/>
					
				
					<text>25E</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_2-A</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 2-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Representative images of vasculature stained by an antibody anti-CD31 in A375 xenografts treated as indicated. Bar graphs indicate quantitative micro vessel density (MVD) and micro vessel area (MVA) analysis (n=5 tumors), ***P &amp;lt; 0.001 versus vehicle (MVD: bevacizumab P = 5.94E-25; COMBO P = 1.84E-04) (MVA: PLX4720 P = 4.98E-09; bevacizumab P = 1.16E-19; COMBO P = 3.00E-08).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:vessel</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="6" offset="154"/>
					
				
					<text>vessel</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:vessel</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="6" offset="185"/>
					
				
					<text>vessel</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:CD31</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="4" offset="69"/>
					
				
					<text>CD31</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_2-B</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 2-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Representative images of vessel lumen in A375 xenografts treated as indicated. Bar graphs indicate the quantitative analysis of lumen diameters in A375 and COLO205 xenografts (n=3 tumors), *P &amp;lt; 0.05, **P &amp;lt; 0.01, ***P &amp;lt; 0.001 versus vehicle (A375: PLX4720 P = 0.0078; COMBO P = 0.0012) (COLO205: PLX4720 P = 2.01E-06; COMBO P = 1.33E-07).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:vessel</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="6" offset="29"/>
					
				
					<text>vessel</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_2-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 2-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C) Representative images of perfusing fluorescent beads and their relationship with microvessels in A375 xenografts treated as indicated. Bar graphs indicate the % of CD31+ vessels co-stained with fluorescent beads (n=4 tumors), **P &amp;lt; 0.01 versus vehicle (PLX4720 P = 0.0031; COMBO P = 0.0033).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_2-D</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 2-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_2-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) Representative images of hypoxia marker pimonidazole in A375 xenografts treated as indicated. Bar graphs show the % of tumor hypoxic area in A375 and COLO205 xenografts (n=5 tumors), **P &amp;lt; 0.01, ***P &amp;lt; 0.001 versus vehicle (A375: PLX4720 P = 6.94E-12; COMBO P = 3.34E-12) (COLO205: PLX4720 P = 0.0015; bevacizumab P = 0.0004; COMBO P = 0.0003).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_3-D</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 3-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) GSEA enrichment plots for &quot;Reactome Cytokine Signaling in Immune System&quot; and &quot;Reactome Innate Immune System&quot; (upper panels) and &quot;Reactome Extracellular Matrix Organization&quot; and &quot;Reactome Collagen Formation&quot; (lower panels) highlight significant enrichment of the pathways relative to the immune response and a decreased expression of the pathways relative to extracellular matrix remodeling in COMBO treated tumors as compared to the other treatments (vehicle, PLX4720, bevacizumab).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:Signaling</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="9" offset="49"/>
					
				
					<text>Signaling</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_3-E</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 3-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_3-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(E) Heatmap representation of gene expression changes within the &quot;Reactome Innate Immune System&quot; (left panel) and &quot;Reactome Extracellular matrix Organization&quot; (right panel) gene set. Genes in heatmaps are shown in rows and samples are shown in columns. Expression level is represented as a gradient from high (red) to low (blue). V, P, B and C respectively indicate vehicle, PLX4720, bevacizumab and COMBO.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_4-A-B</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 4-A-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-A-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Representative images of leukocytes infiltration determined by immunofluorescence CD45 staining in of A375 xenografts treated as indicated. Bar graphs indicate the CD45+ area/tumor area in A375 and COLO205 xenografts (n=5 tumors), ***P &amp;lt; 0.001 versus vehicle (A375: P = 2.19E-20) (COLO205: P = 1.81E-06). (B) Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the F4/80+ area/tumor area in A375 and COLO205 xenografts (n=5 tumors) ***P &amp;lt; 0.001 versus vehicle (A375: COMBO P = 3.42E-13) (COLO205: COMBO P = 1.94E-06).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:CD45</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="4" offset="86"/>
					
				
					<text>CD45</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:CD45</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="168"/>
					
				
					<text>CD45</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:81E</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="3" offset="300"/>
					
				
					<text>81E</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_4-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 4-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C) A375 xenograft tumors after 14 days of treatment were subjected to FACS and tumor infiltrate was analyzed. Gating strategy for CD45+ cells and graph showing the quantification of FACS analysis of infiltrating CD45+ leukocytes in vehicle (n=4 tumors) compared to COMBO (n=6 tumors) treated tumors, **P &amp;lt; 0.01 versus vehicle (P = 0.0064).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:tumor</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="19"/>
					
				
					<text>tumor</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:tumor</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="5" offset="80"/>
					
				
					<text>tumor</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:tumor</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="5" offset="246"/>
					
				
					<text>tumor</text>
					
			
				</annotation>
				
			
				<annotation id="4">
					
				
					<infon key="type">protein:tumor</infon>
					
				
					<infon key="sourcedata_figure_annot_id">4</infon>
					
				
					<infon key="sourcedata_article_annot_id">4</infon>
					
				
					<location length="5" offset="277"/>
					
				
					<text>tumor</text>
					
			
				</annotation>
				
			
				<annotation id="5">
					
				
					<infon key="type">protein:tumor</infon>
					
				
					<infon key="sourcedata_figure_annot_id">5</infon>
					
				
					<infon key="sourcedata_article_annot_id">5</infon>
					
				
					<location length="5" offset="293"/>
					
				
					<text>tumor</text>
					
			
				</annotation>
				
			
				<annotation id="6">
					
				
					<infon key="type">protein:CD45</infon>
					
				
					<infon key="sourcedata_figure_annot_id">6</infon>
					
				
					<infon key="sourcedata_article_annot_id">6</infon>
					
				
					<location length="4" offset="131"/>
					
				
					<text>CD45</text>
					
			
				</annotation>
				
			
				<annotation id="7">
					
				
					<infon key="type">protein:CD45</infon>
					
				
					<infon key="sourcedata_figure_annot_id">7</infon>
					
				
					<infon key="sourcedata_article_annot_id">7</infon>
					
				
					<location length="4" offset="213"/>
					
				
					<text>CD45</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_4-D</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 4-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_4-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) Graph showing the quantification of FACS analysis of infiltrating F4/80+ macrophages and CD11c+MHCII+ dendritic cells in vehicle (n=4 tumors) compared to COMBO (n=6 tumors) treated tumors, **P &amp;lt; 0.01 versus vehicle (TAM P = 0.0061; DC P = 0.0091).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-A</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Real-time quantitative PCR of the indicated genes (M1-like and M2-like macrophages markers) of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) compared with vehicle after normalization for housekeeping gene TBP (n=3 tumors), (*P &amp;lt; 0.05, **P &amp;lt; 0.01, ***P &amp;lt; 0.001 versus vehicle (PLX4720: m-Arg1 P = 5.65E-06) (bevacizumab: m-Ccl5 P = 0.025) (COMBO: m-Ccl5 P = 0.0070; m-Cd40 P = 0.00099; m-Cxcl10 P = 0.043; m-Cxcl9 P = 0.046; m-Il1b P = 0.0367; m-Stat1 P = 0.049; m-Tlr2 = 0.00182; m-Arg-1 P = 0.0013).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:Stat1</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="514"/>
					
				
					<text>Stat1</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:Arg1</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="356"/>
					
				
					<text>Arg1</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:Il1b</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="4" offset="495"/>
					
				
					<text>Il1b</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-B</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-B</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-B</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Representative images of COMBO-treated tumor sections co-stained with an antibody against CD68 and an antibody anti-CCR7 (M1-like polarization) or anti-CD206 (M2-like polarization).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:CD206</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="156"/>
					
				
					<text>CD206</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:CCR7</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="120"/>
					
				
					<text>CCR7</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(C) Graphs showing the quantification of FACS analysis of infiltrating F4/80+ tumor macrophages and average percentage of median fluorescence intensity (MFI) of TNFα+ or INOS+ on F4/80+ cells after ex vivo stimulation with PMA and ionomycin in vehicle (n=4 tumors) and COMBO (n=6 tumors), *P &amp;lt; 0.05 versus vehicle (TNFα P = 0.037; INOS = 0.038).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:TNFα</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="161"/>
					
				
					<text>TNFα</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:TNFα</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="5" offset="316"/>
					
				
					<text>TNFα</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-D</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) Graphs showing the quantification of FACS analysis of infiltrating CD11b+Ly6C+ tumor monocytes and average percentage of MFI of TNFα+ or INOS+ on CD11b+Ly6C+ cells after ex vivo stimulation with PMA and ionomycin in vehicle (n=4 tumors) and COMBO (n=6 tumors), *P &amp;lt; 0.05 versus vehicle (TNFα P = 0.048; INOS = 0.038).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:infiltrating</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="12" offset="58"/>
					
				
					<text>infiltrating</text>
					
			
				</annotation>
				
			
				<annotation id="2">
					
				
					<infon key="type">protein:Ly6C</infon>
					
				
					<infon key="sourcedata_figure_annot_id">2</infon>
					
				
					<infon key="sourcedata_article_annot_id">2</infon>
					
				
					<location length="4" offset="77"/>
					
				
					<text>Ly6C</text>
					
			
				</annotation>
				
			
				<annotation id="3">
					
				
					<infon key="type">protein:Ly6C</infon>
					
				
					<infon key="sourcedata_figure_annot_id">3</infon>
					
				
					<infon key="sourcedata_article_annot_id">3</infon>
					
				
					<location length="4" offset="157"/>
					
				
					<text>Ly6C</text>
					
			
				</annotation>
				
			
				<annotation id="4">
					
				
					<infon key="type">protein:TNFα</infon>
					
				
					<infon key="sourcedata_figure_annot_id">4</infon>
					
				
					<infon key="sourcedata_article_annot_id">4</infon>
					
				
					<location length="5" offset="132"/>
					
				
					<text>TNFα</text>
					
			
				</annotation>
				
			
				<annotation id="5">
					
				
					<infon key="type">protein:TNFα</infon>
					
				
					<infon key="sourcedata_figure_annot_id">5</infon>
					
				
					<infon key="sourcedata_article_annot_id">5</infon>
					
				
					<location length="5" offset="292"/>
					
				
					<text>TNFα</text>
					
			
				</annotation>
				
			
				<annotation id="6">
					
				
					<infon key="type">protein:MFI</infon>
					
				
					<infon key="sourcedata_figure_annot_id">6</infon>
					
				
					<infon key="sourcedata_article_annot_id">6</infon>
					
				
					<location length="3" offset="125"/>
					
				
					<text>MFI</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-E</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(E) Graph showing the quantification of circulating CD11b+Ly6C+ monocytes in peripheral blood analyzed by FACS in vehicle- (n=4 tumors) and COMBO- (n=6 tumors) treated tumors.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:circulating</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="11" offset="40"/>
					
				
					<text>circulating</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_5-F</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 5-F</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_5-F</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(F) Cell viability measured as fluorescence intensity of ZsGreen-A375 cells co-cultured with cells isolated from xenograft treated with vehicle or COMBO with after 48h. Data are representative of one experiment out of two done in triplicate *P &amp;lt; 0.05 versus vehicle (P = 0.046).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:ZsGreen</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="7" offset="57"/>
					
				
					<text>ZsGreen</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_6-A-B-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 6-A-B-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-A-B-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Representative images of collagen deposition determined by collagen I immunofluorescent staining in A375 xenografts treated as indicated. Bar graphs indicate the collagen I+ area/tumor area (n=5 tumors), ***P &amp;lt; 0.001 versus vehicle (P = 2.93E-06). (B) Representative images of CAF density determined by α-SMA immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate α-SMA+ area/tumor area (n=5 tumors), ***P &amp;lt; 0.001 versus vehicle (P = 0.0006). (C) Representative images of Lysyl Oxidase enzyme determined by LOX immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the LOX+ area/tumor area (n=3 tumors), *P &amp;lt; 0.05 versus vehicle (bevacizumab P = 0.033; COMBO P = 0.040).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:enzyme</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="6" offset="526"/>
					
				
					<text>enzyme</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_6-E</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 6-E</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-E</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(E) Quantitative Real-time PCR of h-TGFB1 and m-Tgfb1 of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) compared with vehicle after normalization for the housekeeping gene TBP (n=3 tumors), *P &amp;lt; 0.05 versus vehicle (P = 0.043).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_6-F</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 6-F</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_6-F</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(F) Western blot for human TGFβ in total protein extract from A375 tumors treated as indicate. Vinculin was used as an internal control.</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:TGFβ</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="5" offset="27"/>
					
				
					<text>TGFβ</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_7-A</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 7-A</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-A</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(A) Effect of clodronate liposomes on tumor growth inhibition induced by COMBO treatment in in mice bearing A375 tumors. Tumor growth is expressed as % change of the initial tumor. Macrophage depletion by clodronate liposome enhanced the tumor growth of tumors treated with the combination of PLX4720 and bevacizumab (n=5 mice/group), *P &amp;lt; 0.05, ***P &amp;lt; 0.001 versus vehicle (vehicle Clodronate P = 0.049, COMBO P = 5.72E-06) ŦP &amp;lt; 0.05 compared to COMBO (P = 0.033).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:72E</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="417"/>
					
				
					<text>72E</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_7-B-C</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 7-B-C</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-B-C</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(B) Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the F4/80+ area/tumor (n=3 tumors), ***P &amp;lt; 0.001 versus vehicle (P = 1.53E-25). (C) Representative images of collagen deposition determined by collagen I immunofluorescence staining in A375 xenografts treated as indicated. Bar graphs indicate the collagen I+ area/tumor (n=3 tumors).</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_7-D</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 7-D</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-D</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(D) Waterfall plots showing the percent change in volume (relative to the initial tumor volume) for the individual A375 xenografts in each treatment group (vehicle, PLX4720, bevacizumab and COMBO) from week 1 to week 6.</text>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_7-E-F</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 7-E-F</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-E-F</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(E) Representative images of macrophage infiltration determined by F4/80 immunofluorescence staining in a responder and a relapsing A375 xenografts. Bar graphs indicate the F4/80+ area/tumor (n=3 mice), ***P &amp;lt; 0.001 versus vehicle (P = 1.25E-06). (F) Representative images of collagen deposition determined by collagen I immunofluorescence staining in a responder and a relapsing A375 xenografts. Bar graphs indicate the collagen I+ area/tumor (n=3 mice), ***P &amp;lt; 0.001 versus vehicle (P = 4.03E-05).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:25E</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="3" offset="238"/>
					
				
					<text>25E</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		
	
		<document>
			
		
			<id>5286370 Figure_7-G</id>
			
		
			<infon key="sourcedata_document">2602</infon>
			
		
			<infon key="doi">10.15252/emmm.201505774</infon>
			
		
			<infon key="pmc_id">5286370</infon>
			
		
			<infon key="figure">Figure 7-G</infon>
			
		
			<infon key="sourcedata_figure_dir">Figure_7-G</infon>
			
		
			<passage>
				
			
				<offset>0</offset>
				
			
				<text>(G) Real-time quantitative PCR of h-TGFB1 of A375 xenograft treated with PLX4720, bevacizumab or COMBO. Data are presented as expression fold change (log2) of relapsing tumors compared to responder tumors after normalization for housekeeping gene TBP (n=3 tumors) ***P &amp;lt; 0.001 versus vehicle (P = 0.0006).</text>
				
			
				<annotation id="1">
					
				
					<infon key="type">protein:relapsing</infon>
					
				
					<infon key="sourcedata_figure_annot_id">1</infon>
					
				
					<infon key="sourcedata_article_annot_id">1</infon>
					
				
					<location length="9" offset="159"/>
					
				
					<text>relapsing</text>
					
			
				</annotation>
				
		
			</passage>
			
	
		</document>
		

	</collection>
